<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">thealth</journal-id><journal-title-group><journal-title xml:lang="ru">Здравоохранение Таджикистана</journal-title><trans-title-group xml:lang="en"><trans-title>Health care of Tajikistan</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">0514-2415</issn><publisher><publisher-name>Редакция журнала «Здравоохранение Таджикистана»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.52888/0514-2515-2023-357-2-105-112</article-id><article-id custom-type="elpub" pub-id-type="custom">thealth-462</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Статьи</subject></subj-group></article-categories><title-group><article-title>Туберкулез с множественной  лекарственной устойчивостью в период пандемии COVID-19  в г. Душанбе</article-title><trans-title-group xml:lang="en"><trans-title>Multi-drug-resistant tuberculosis in COVID-19 pandemic period, Dushanbe</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тиллоева</surname><given-names>З. Х.</given-names></name><name name-style="western" xml:lang="en"><surname>Tilloeva</surname><given-names>Z. H.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Тиллоева Зулфия Хайбуллоевна - врач-эпидемиолог, ГУ «Городская дезинфекционная станция»</p><p>г. Душанбе, проспект А. Дониш 16;</p><p>Тел: +992934477353</p></bio><bio xml:lang="en"><p>Tilloeva Zulfiya Khaybulloevna - doctor-epidemiologist</p><p>Dushanbe, A. Donish Ave. Donish 16</p><p>Tel: +992934477353</p></bio><email xlink:type="simple">ztilloeva@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мирзоев</surname><given-names>А. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Mirzoev</surname><given-names>A. S.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ГУ «Городская дезинфекционная станция»</institution><country>Таджикистан</country></aff><aff xml:lang="en"><institution>State Institution “City Disinfection Station”</institution><country>Tajikistan</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ГУ «Научно-исследовательский институт профилактической медицины Таджикистана»; ГОУ «Институт последипломного образования в сфере здравоохранения Республики Таджикистан»</institution><country>Таджикистан</country></aff><aff xml:lang="en"><institution>State Institution “Research Institute of Preventive Medicine of Tajikistan”; State Educational Institution “Institute of Postgraduate Education in Healthcare of the Republic of Tajikistan”</institution><country>Tajikistan</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>13</day><month>07</month><year>2023</year></pub-date><volume>0</volume><issue>2</issue><fpage>105</fpage><lpage>112</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Тиллоева З.Х., Мирзоев А.С., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Тиллоева З.Х., Мирзоев А.С.</copyright-holder><copyright-holder xml:lang="en">Tilloeva Z.H., Mirzoev A.S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.zdrav.tj/jour/article/view/462">https://www.zdrav.tj/jour/article/view/462</self-uri><abstract><sec><title>Цель исследования</title><p>Цель исследования. Определить изменения в демографических и клинико-эпидемиологических характеристиках больных туберкулёзом с множественной лекарственной устойчивостью возбудителя в период пандемии COVID-19.</p><p>Материал и методы исследования. Кросс-секционное исследование включало больных туберкулёзом с множественной лекарственной устойчивостью возбудителя (ТБ с МЛУ МБТ), зарегистрированных в городе Душанбе до (2017-2019) и в период пандемии COVID-19 (2020-2021).</p><p>Результаты исследования и их обсуждение. Средний возраст пациентов до пандемии COVID-19 составил 36,5±16,9 (1,7 -79,4 лет), в период пандемии 34,4±17 лет (2,9-80,2). В период пандемии отмечено статистически значимое увеличение доли работающих среди больных туберкулёзом с множественной лекарственной устойчивостью возбудителя по сравнению с безработными (ОР =1,4; 95% ДИ 1,02-1,91; р=0,05), увеличение доли пациентов с распадом легочной ткани как у впервые выявленных (ОР 3,4; 95%ДИ 1,99-5,87; р &lt;0,001), так и у повторных больных (ОР 4,2; 95%ДИ 1,38-12,99; р =0,002,), а также больных туберкулёзом внелёгочной локализации (ОР= 1,7; 95% ДИ 1,34-2,22; р &lt;0,001), что указывает на неблагополучную эпидемиологическую ситуацию по туберкулёзу с множественной лекарственной устойчивостью возбудителя. Статистически значимых изменений в регистрации сопутствующих заболеваний не отмечено.</p></sec><sec><title>Заключение</title><p>Заключение. Рекомендуется предпринять меры по раннему выявлению больных туберкулёзом с множественной лекарственной\рифампицин устойчивостью возбудителя, усилению внедрения мер противотуберкулёзного инфекционного контроля.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. To evaluate the shifts in demographic, clinical, and epidemiological characteristics of patients with multidrugresistant tuberculosis (MDR TB) amidst the COVID-19 pandemic.</p></sec><sec><title>Materials and Methods</title><p>Materials and Methods. A cross-sectional study was conducted on patients with MDR TB registered in Dushanbe, before (2017-2019) and during the COVID-19 pandemic (2020-2021).</p></sec><sec><title>Results</title><p>Results. The average age of patients prior to the COVID-19 pandemic was 36.5±16.9 years (1.7-79.4), whereas during the COVID-19 period, it was 34.4±17 years (2.9-80.2). The pandemic era witnessed a statistically significant rise in the proportion of workers among MDR TB patients compared to the unemployed (OR = 1.4; 95% CI 1.02-1.91; p = 0.05). Furthermore, an increase was observed in the proportion of patients with lung destruction in both newly diagnosed (OR 3.4; 95% CI 1.99–5.87; p&lt;0.001) and previously treated patients (OR 4.2; 95% CI 1.38–12.99; p =0.002). There was also an increase in extrapulmonary tuberculosis registration (OR=1.7; 95% CI 1.34-2.22; p&lt;0.001), indicating an unfavorable epidemiological situation in terms of MDR-TB. However, there were no statistically significant changes in the registration of concomitant diseases.</p></sec><sec><title>Conclusion</title><p>Conclusion. We recommend the improvement of TB infection prevention and control measures at all levels, as well as the enhancement of early detection of TB and MDR TB patients by primary health care workers.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>туберкулёз</kwd><kwd>множественная лекарственная устойчивость</kwd><kwd>COVID-19</kwd></kwd-group><kwd-group xml:lang="en"><kwd>Tuberculosis</kwd><kwd>multidrug resistance</kwd><kwd>COVID-19 pandemic</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Васильева И.А. Эпидемическая ситуация по туберкулезу в годы пандемии COVID-19 – 2020-2021 гг. / И.А. Васильева, В.В. Тестов, С.А. Стерликов // Туберкулез и болезни легких. - 2022. - №100(3) - С. 6-12.</mixed-citation><mixed-citation xml:lang="en">Vasileva I.A. Epidemicheskaya situatsiya po tuberkulezu v gody pandemii COVID-19 – 2020-2021 gg. [Epidemic situation for tuberculosis in the years of the COVID-19 pandemic - 2020-2021.]. Tuberkulez i bolezni legkikh - Tuberculosis and lung diseases, 2022, No. 100 (3), pp. 6-12.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Махмудова П.У. Эффективность лечения больных с лекарственно устойчивыми формами туберкулёза лёгких в Республике Таджикистан / П.У. Махмудова, Р.У. Махмудова, К.А. Закирова // Вестник Авиценны. - 2018. – Т 20, №2-3. - C. 235–239.</mixed-citation><mixed-citation xml:lang="en">Makhmudova P.U. Effektivnost lecheniya bolnykh s lekarstvenno ustoychivymi formami tuberkulyoza lyogkikh v Respublike Tadzhikistan [Effectiveness of Treatment of Patients with DrugResistant Forms of Pulmonary Tuberculosis in the Republic of Tajikistan]. Vestnik Avitsenny - Avicenna Bulletin, 2018, Vol. 20, No. 2-3, pp. 235–239.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Министерство здравоохранения и социальной защиты населения Республики Таджикистан. Здоровье населения и деятельность учреждений здравоохранения в Республике Таджикистан. - 2015-2020. - Душанбе.</mixed-citation><mixed-citation xml:lang="en">Ministerstvo zdravookhraneniya i sotsialnoy zashchity naseleniya Respubliki Tadzhikistan. Zdorove naseleniya i deyatelnost uchrezhdeniy zdravookhraneniya v Respublike Tadzhikistan [Ministry of Health and Social Protection of the Republic of Tajikistan. Population Health and Activities of Health Care Institutions in the Republic of Tajikistan]. Dushanbe, 2015-2020.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Национальная программа защиты населения от туберкулёза в Республике Таджикистан на 20212025 годы от 27 февраля 2021 года, №49. Доступно в: http://www.adlia.tj/show_doc.fwx?Rgn=138961</mixed-citation><mixed-citation xml:lang="en">Natsionalnaya programma zashchity naseleniya ot tuberkulyoza v Respublike Tadzhikistan na 20212025 gody ot 27 fevralya 2021 goda, №49 [National program to protect the population from tuberculosis in the Republic of Tajikistan for 2021-2025, February 27, 2021, №49.].</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Тиллоева З.Х. Имплементационное исследование в профилактике и контроле туберкулёза с лекарственной устойчивостью в период пандемии COVID-19 в Душанбе / З.Х. Тиллоева // Вестник Авиценны. - 2022. - №24(2). - С. 204-217. Available from: https://doi.org/10.25005/2074-0581-2022-242-204-217</mixed-citation><mixed-citation xml:lang="en">Available at: http://www.adlia.tj/show_doc.fwx?Rgn=138961</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Tilloeva Z.Kh. Implementatsionnoe issledovanie v profilaktike i kontrole tuberkulyoza s lekarstvennoy ustoychivostyu v period pandemii COVID-19 v Dushanbe [An Implementation Study in the Prevention and Control of Drug-Resistant Tuberculosis in the COVID-19 Pandemic in Dushanbe]. Vestnik Avitsenny - Avicenna Bulletin, 2022, No. 24 (2), pp. 204-217.</mixed-citation><mixed-citation xml:lang="en">Tilloeva Z.Kh. Implementatsionnoe issledovanie v profilaktike i kontrole tuberkulyoza s lekarstvennoy ustoychivostyu v period pandemii COVID-19 v Dushanbe [An Implementation Study in the Prevention and Control of Drug-Resistant Tuberculosis in the COVID-19 Pandemic in Dushanbe]. Vestnik Avitsenny - Avicenna Bulletin, 2022, No. 24 (2), pp. 204-217.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Dadu A. Drug-resistant tuberculosis in eastern Europe and central Asia: a time-series analysis of routine surveillance data. The Lancet. Infectious diseases, 2020, No. 2 (20), pp. 250–258.</mixed-citation><mixed-citation xml:lang="en">Dadu A. Drug-resistant tuberculosis in eastern Europe and central Asia: a time-series analysis of routine surveillance data. The Lancet. Infectious diseases, 2020, No. 2 (20), pp. 250–258.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Makhmudova M. Risk factors for unfavourable treatment outcomes among rifampicin-resistant tuberculosis patients in Tajikistan. The international journal of tuberculosis and lung disease: the official journal of the International Union against Tuberculosis and Lung Disease, 2019, Vol. 23, No. 3, pp. 331–336.</mixed-citation><mixed-citation xml:lang="en">Makhmudova M. Risk factors for unfavourable treatment outcomes among rifampicin-resistant tuberculosis patients in Tajikistan. The international journal of tuberculosis and lung disease: the official journal of the International Union against Tuberculosis and Lung Disease, 2019, Vol. 23, No. 3, pp. 331–336.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Pirmahmadzoda B. Treatment success using novel and adapted treatment regimens in registered DR-TB children in Dushanbe, Tajikistan, 2013-2019. The Journal of Infection in Developing Countries, 2021, No. 9 (15), pp. 7S-16S.</mixed-citation><mixed-citation xml:lang="en">Pirmahmadzoda B. Treatment success using novel and adapted treatment regimens in registered DR-TB children in Dushanbe, Tajikistan, 2013-2019. The Journal of Infection in Developing Countries, 2021, No. 9 (15), pp. 7S-16S.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Scott C. Evaluation of the Tuberculosis Infection Control Training Center, Tajikistan, 20142015. The international journal of tuberculosis and lung disease: the official journal of the International Union against Tuberculosis and Lung Disease, 2017, No. 5 (21), pp. 579–585.</mixed-citation><mixed-citation xml:lang="en">Scott C. Evaluation of the Tuberculosis Infection Control Training Center, Tajikistan, 20142015. The international journal of tuberculosis and lung disease: the official journal of the International Union against Tuberculosis and Lung Disease, 2017, No. 5 (21), pp. 579–585.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Tajikistan - Population Density - Humanitarian Data Exchange. 2022</mixed-citation><mixed-citation xml:lang="en">Tajikistan - Population Density - Humanitarian Data Exchange. 2022</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Available at: https://data.humdata.org/dataset/worldpop-population-density-for-tajikistan?</mixed-citation><mixed-citation xml:lang="en">Available at: https://data.humdata.org/dataset/worldpop-population-density-for-tajikistan?</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">World Health Organization. Global tuberculosis report 2020. World Health Organization Publ., 2021.</mixed-citation><mixed-citation xml:lang="en">World Health Organization. Global tuberculosis report 2020. World Health Organization Publ., 2021.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Available at: https://www.who.int/publications/i/item/9789240037021.</mixed-citation><mixed-citation xml:lang="en">Available at: https://www.who.int/publications/i/item/9789240037021.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
